Nanobody-Based high-performance immunosorbent for selective beta 2-microglobulin purification from blood

Peptide Linker Affecting the Activity Retention Rate of VHH in Immunosorbents

“…As shown in Figure S3, the adsorption of β2MG on the immunosorbents fitted very well with the Langmuir adsorption isotherm. All the correlation coefficients (R 2 ) of the rearranged Langmuir adsorption isotherm model for β2MG were above 0.99, indicating that the adsorption of β2MG on the VHH-based immunosorbent was consistent with the Langmuir adsorption isotherm model and It should be noted that the VHH density could be controlled easily by changing the reaction time and material input [39]. Here we choose a moderate material input to avoid wasting protein, the immobilization performance under the present condition was fairly good compared with previous work that generated a VHH density of 1.2 mg/mL gel [7].…”

“…It should be noted that the VHH density could be controlled easily by changing the reaction time and material input [39]. Here we choose a moderate material input to avoid wasting protein, the immobilization performance under the present condition was fairly good compared with previous work that generated a VHH density of 1.2 mg/mL gel [7].…”

Nanobodies: new avenue to treat kidney disease

“…In this specific example, a highly selective immunosorbent was prepared using a β2-microtubulin- (β2M-) specific nanobody to prospectively purify β2M from the blood of patients with dialysis-related amyloidosis (DRA). The accumulation of β2M is a serious side effect in patients with end-stage kidney disease, indicating that selective extracorporeal removal of β2M is a promising method to delay the onset and progression of DRA (Huang et al 2020a ).…”

Enhanced β2-microglobulin binding of a “navigator” molecule bearing a single-chain variable fragment antibody for artificial switching of metabolic processing pathways

“…Although blood purification therapies, including hemodiafiltration and hemoadsorption, are performed clinically to remove β2-m from the bloodstream, serum proteins, such as albumin, insulin, and lysozyme, are also removed unexpectedly. [21][22][23] Thus, anti-β2-m antibodybased adsorbents have been studied, for specific removal of β2-m. 11,24,25 However, the volume of the adsorbents was only a bench scale (<0.1 mL or 1 mg). 11,24,25 Previously, we developed transgenic Bombyx mori silkworm strains that produce scFvfused silk fibroin proteins, which were fabricated into powders and films without losing the antigen-binding activity of scFv.…”

“…[21][22][23] Thus, anti-β2-m antibodybased adsorbents have been studied, for specific removal of β2-m. 11,24,25 However, the volume of the adsorbents was only a bench scale (<0.1 mL or 1 mg). 11,24,25 Previously, we developed transgenic Bombyx mori silkworm strains that produce scFvfused silk fibroin proteins, which were fabricated into powders and films without losing the antigen-binding activity of scFv. [12][13][14] One transgenic B. mori silkworm produces approximately 0.5-2.5 mg of fusion silk fibroin proteins, [26][27][28] and silk fibroin fibers are used as filtration/separation materials.…”